MSD presented us the new data on posaconazole (iv and tbl formulation) as well as new data on two antibtiotics against Gram neg and Gram post bacteria(Sivextro, Zerbaxa) Presenter:  Efi Mintzia Brand & Customer ManagerMSD Participants: all medical staff, Prof. Marangos

An excellent approach on how one could make decisions on transplant or not to transplant (and when) in AML patients.  Presenter: Spyridonidis Participants: all medical staff

We discussed the clinical significance of AML mutations which now can be detected with NGS AML panel. detected muations can be used for prognosis, for targeted therapy or prediction fo response to current therpaies. Presenter: Spyridondis Participants: all medical staff

NGS analysis can nowadays detect new mutations in AML. We discuss their prognostic and therpauetic implications Presenter: Spyridonidis Participants: all medical staff

We discusssed the curretn progresses in cancer immunotherpay and the way that we could overcome the primary, adaptive and aquired resistance Presenter: Spyridonidis Participants: all medical staff

To answer whether a VUD or haplo or moreover sibling is the best donmor, we need other tools beyond classical HAL which could predict GvHD and GvL beter. We presented two intersting studies using genome wide analysis for minor HALa and cimputerized epitope prediction...

We discussed possibilities to enhance immune reconsitution after transplnatation. A review apper was presented. Besides pre-HCT and inter HCT measures we aslso discussed the interventions that can be done after transplantation, especailly cellular therapy (CTLs). The available pharmacological measures with IL-2 and sex steroid abaltio...

 we discusssed how to select the best haploidentical donor in T-cell replete Haploidentical Transplantation. The algorithm was implemented in our policy.  Presenter: Spyridonidis Participants: all medical staff

We presented the papers/debate  regarding which is the better donor (VUD or haplo) published in Blood Advances. Presenter: A. Spyridonidis Participants: All medical staff.     Related haploidentical donors are a better choice than matched unrelated donors: Counterpoi"Related haploidentical donors are a better choice than matched unrelateddonors: Counterpoint" by Bronwen E....

We ahve been informed about the subcutan administration of immunoglobulins with the use of hyalorunidase. This troute of administration is attractive for our patients who have difficult venous access. Conceerns are possible infections at the site of injection, something which we will evaluate. Presenter: Medical...

Στα πλαίσια του εκπαιδευτικού προγράμματος της ΜΜΜΟ, την Τρίτη 31/1/17 δόθηκε διάλεξη από την κα Κυριάκου της Δερματολογικής κλινικής του ΠΓΝΠ με θέμα : Διάγνωση δερματικού GVHD από τη πλευρά του δερματολόγου. Η διάλεξη πραγματοποιήθηκε στο γραφείο ιατρών της ΜΜΜΟ, στις 13:00 Παρόντες¨όλο το ιατρικό προσωπικό

Keypoints that discussed: prevalance at out Hospital, sources of infection, prophylactic measures.  Risk-adapted strategy according to identifying those patients at higher risk for MDR GNB infectiona dn previous history of colonization. The value of surveillance studies. How to approach MDR GNB infections in neutropenic patients? We adapted...

Diagnosis and treatment of BO after trasnplantation is a major challenge. Distinguish between BO and BOOP (new terminology COP-cryptogenic organizing pneumonia) is of clinicaql importance because f the differetent therpauetic approach. The importnace of lung function testst and correct interpretation was discussed and will be...

We discussed the recent publication in Blood regarding current guideliens in the managment of AML. These guideliens are imp;lementedd in our policy. Reagrding flt3ITD + AML we aim to participate in a multicenter study with the prophylactic use of a new inhibitor after trasnplantation. Lecturer:...

Clinical case: a patient has only mismatched donors. Whioch one should we choose. We discussed these issues of HLA matching, GvH and HvG diirection, the importance of differtent HLA mismatches,  premissive mismatches vs low expression alleles. Three sceanrios were discussed in detail Lecturer: Prof. Spyridonidis Participants: all...

Clinical case: PAtient wilt ALL seeks consulation for transplant or not. What is the value of MRD diagnostic? How do we perform MRD diagnostic Discussion: We discussed the challenges of MRD. The new nomenclature names MRD not minimal residula disease but measurable residual disease. Howerver...

During the last years we used different sytems to evaluate and grade chronic GvHD, which were implenmeted in our Unit. Starting form the classical limited/extensive categorization, we used the last years the NIH mild/severe/moderate classification. We dicussed a nce review form Lee regarding cGvHD...

Our previous evaluation, publisehd in BMT revealed the higher GvHD and TRM in mismatched PBSCT. We discussed our prospective study adding either MMF or 1 day post-Cy in our current 20mg Camoth anti GvHD practice.We also discussed the paper "Prospective study of nonmyeloablative, HLA-mismatched...